Evidence map›Paper›PMID 36084080›Full record

ArticlePloS one2022

Development of lab score system for predicting COVID-19 patient severity: A retrospective analysis.

Arnab Sarkar, Surojit Sanyal, Agniva Majumdar, Devendra Nath Tewari, Uttaran Bhattacharjee, Juhi Pal, Alok Kumar Chakrabarti, Shanta Dutta

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Beware the IBM SPSS statisticsInternal and emergency medicine · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arnab SarkarICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Surojit SanyalICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Agniva MajumdarICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Devendra Nath TewariICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Uttaran BhattacharjeeICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Juhi PalICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.
Alok Kumar ChakrabartiICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.ORCID 0000-0001-7611-909X
Shanta DuttaICMR- National Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, India.ORCID 0000-0002-6897-7390

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo develop an accurate lab score based on in-hospital patients' potent clinical and biological parameters for predicting COVID-19 patient severity during hospital admission.

methodsTo conduct this retrospective analysis, a derivation cohort was constructed by including all the available biological and clinical parameters of 355 COVID positive patients (recovered = 285, deceased = 70), collected in November 2020-September 2021. For identifying potent biomarkers and clinical parameters to determine hospital admitted patient severity or mortality, the receiver operating characteristics (ROC) curve and Fischer's test analysis was performed. Relative risk regression was estimated to develop laboratory scores for each clinical and routine biological parameter. Lab score was further validated by ROC curve analysis of the validation cohort which was built with 50 COVID positive hospital patients, admitted during October 2021-January 2022.

resultsSensitivity vs. 1-specificity ROC curve (>0.7 Area Under the Curve, 95% CI) and univariate analysis (p<0.0001) of the derivation cohort identified five routine biomarkers (neutrophil, lymphocytes, neutrophil: lymphocytes, WBC count, ferritin) and three clinical parameters (patient age, pre-existing comorbidities, admitted with pneumonia) for the novel lab score development. Depending on the relative risk (p values and 95% CI) these clinical parameters were scored and attributed to both the derivation cohort (n = 355) and the validation cohort (n = 50). ROC curve analysis estimated the Area Under the Curve (AUC) of the derivation and validation cohort which was 0.914 (0.883-0.945, 95% CI) and 0.873 (0.778-0.969, 95% CI) respectively.

conclusionThe development of proper lab scores, based on patients' clinical parameters and routine biomarkers, would help physicians to predict patient risk at the time of their hospital admission and may improve hospital-admitted COVID-19 patients' survivability.

Indexed as

COVID-19PneumoniaHumansLeukocyte CountPrognosisRetrospective StudiesROC Curve

Identifiers

PMID36084080
PMCPMC9462772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.